Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CTSH | P09668 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990720 | 0.86 | CTSK (0.41) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL499190 | 0.77 | CTSK (0.40) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL499191 | 0.77 | CTSK (0.40) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL21574018 | 0.76 | HTR2C (0.42) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL8911411 | 0.76 | HTR2C (0.42) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL27374399 | 0.76 | HTR2C (0.37) | HTR2CSLC6A4HTR2ASIGMAR1ALDH1A1 | |
| SCHEMBL754325 | 0.76 | CTSK (0.37) | CTSK | |
| SCHEMBL15866143 | 0.76 | CTSK (0.40) | CTSKCACNA1B | |
| SCHEMBL6327607 | 0.75 | GPR88 (0.36) | CTSKCTSSHTR2CSLC6A4 | |
| SCHEMBL4803942 | 0.75 | HTR2C (0.38) | CTSKCTSSCTSLCTSBCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417064-B2 | 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417064-B2 | 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417064-B2 | 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7410982-B2 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410982-B2 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410982-B2 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1567501-B1 | PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060058360-A1 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2006-03-16 | — | — | US | disclosed |
| US-20060014779-A1 | 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake | ELI LILLY AND COMPANY (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1587782-A1 | 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | Eli Lilly and Company (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1567501-A1 | PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004043904-A1 | 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043931-A1 | PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014779-A1 | 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake | ADRB3, HTR3C, CHRNB3 | CTSK 3201/4885CTSS 2232/4885CTSL 3012/4885 |
| US-20060058360-A1 | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors | ADRB3, SLC6A2, SLC6A3 | CTSK 2440/4885CTSS 1385/4885CTSL 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.